DXRX vs. AGL, YGEN, ABDX, PRM, GDR, GENI, VRCI, DMTR, LLAI, and LLA
Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Verici Dx (VRCI), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.
Diaceutics vs. Its Competitors
Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. ANGLE's average media sentiment score of 0.55 beat Diaceutics' score of -0.52 indicating that ANGLE is being referred to more favorably in the news media.
Diaceutics has a net margin of -10.90% compared to ANGLE's net margin of -890.91%. Diaceutics' return on equity of -7.15% beat ANGLE's return on equity.
Diaceutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.
Diaceutics currently has a consensus target price of GBX 168.33, suggesting a potential upside of 32.35%. ANGLE has a consensus target price of GBX 40, suggesting a potential upside of 498.00%. Given ANGLE's higher possible upside, analysts plainly believe ANGLE is more favorable than Diaceutics.
52.4% of Diaceutics shares are held by institutional investors. Comparatively, 18.8% of ANGLE shares are held by institutional investors. 34.3% of Diaceutics shares are held by company insiders. Comparatively, 16.2% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
Summary
Diaceutics beats ANGLE on 10 of the 14 factors compared between the two stocks.
Get Diaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Diaceutics Competitors List
Related Companies and Tools
This page (LON:DXRX) was last updated on 7/18/2025 by MarketBeat.com Staff
Free DXRX Stock Alerts